Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15162468rdf:typepubmed:Citationlld:pubmed
pubmed-article:15162468lifeskim:mentionsumls-concept:C0023911lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C1882726lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C0021080lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C0085149lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C0021079lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:15162468lifeskim:mentionsumls-concept:C1627358lld:lifeskim
pubmed-article:15162468pubmed:issue6lld:pubmed
pubmed-article:15162468pubmed:dateCreated2004-5-26lld:pubmed
pubmed-article:15162468pubmed:abstractTextA member of the costimulatory molecule family, inducible costimulator (ICOS), is expressed on activated T cells and plays a critical role in their primary activation and cytokine production. ICOS is involved in different immune phenomena, such as Th1-mediated autoimmune disease and graft rejection. Although blockade of ICOS costimulation theoretically may protect grafts from rejection, a single dose of anti-ICOS antibody did not result in the prolongation of rat liver allograft survival. However, in this article, we report that anti-rat ICOS antibody markedly enhanced the immunosuppressive activity of a suboptimal dose of tacrolimus (FK506). After fully allogenic DA to LEW liver transplantation, recipients received a single injection of tacrolimus (1 mg/kg, intramuscularly) with or without anti-ICOS antibody (1 mg/kg, intravenously). Recipient survival was significantly prolonged in rats treated with both the antibody and suboptimal tacrolimus (median survival time 44 days vs. 28 days with tacrolimus alone, P <.01). The extent of cell infiltration into the graft was closely associated with prolongation of recipient survival. Our findings thus demonstrate that anti-ICOS antibody immunotherapy combined with suboptimal tacrolimus has a synergistic effect in preventing hepatic allograft rejection and that it may induce long-term graft acceptance intimately associated with a marked reduction of intragraft T lymphocyte infiltration.lld:pubmed
pubmed-article:15162468pubmed:languageenglld:pubmed
pubmed-article:15162468pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:citationSubsetIMlld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15162468pubmed:statusMEDLINElld:pubmed
pubmed-article:15162468pubmed:monthJunlld:pubmed
pubmed-article:15162468pubmed:issn1527-6465lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:DaiS JSJlld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:SugawaraYasuh...lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:MakuuchiMasat...lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:LiXiao-KangXKlld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:FuneshimaNaok...lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:SuzukiSeiichi...lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:KimuraHiromit...lld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:EnosawaShinSlld:pubmed
pubmed-article:15162468pubmed:authorpubmed-author:TezukaKatsuna...lld:pubmed
pubmed-article:15162468pubmed:issnTypePrintlld:pubmed
pubmed-article:15162468pubmed:volume10lld:pubmed
pubmed-article:15162468pubmed:ownerNLMlld:pubmed
pubmed-article:15162468pubmed:authorsCompleteYlld:pubmed
pubmed-article:15162468pubmed:pagination743-7lld:pubmed
pubmed-article:15162468pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:meshHeadingpubmed-meshheading:15162468...lld:pubmed
pubmed-article:15162468pubmed:year2004lld:pubmed
pubmed-article:15162468pubmed:articleTitleSignificant enhancement by anti-ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver transplantation.lld:pubmed
pubmed-article:15162468pubmed:affiliationDepartment of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan.lld:pubmed
pubmed-article:15162468pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15162468pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed